Xiang Li earned a PhD from the Chinese Academy of Science, and worked as a postdoctoral fellow at UC Berkeley. He is the member of Chinese “Thousand of People Plan”. Dr Li is the founder and chairman of Peptide Biomedical limited company (acquired by Xinbang Pharmaceutical Co., Ltd.) and the Chairman of Xinbang Pharmaceutical Co., Ltd. (SHE: 002390). He was the first Chinese student in US, who established biomedical and peptide company in Silicon Valley. He also established the first and the largest peptide company in China that provides service outsourcing, diagnostic testing products and peptide drug R&D. He led the team and passed 4 FDA inspections without any error.
Peptide Biochemistry collaborates with both domestic and global pharmaceutical companies in the development of numerous peptide drugs, of which more than 10 have been approved for marketing, and more than 50 has entered Phase I to Phase III clinical. Dr Li also led the IVD business in the company that has obtained 18 510K approvals and 43 CE Marker. He has been awarded many prizes including the China Peptide Contribution Award. Currently, Dr Li is the professor in School of Pharmacy at Pacific University, and has been selected as reviewer and judge for the national new drug approval in China.